Drugs / AXA1665
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04816916 | Jun 2021 → Jun 2022 | hepatic encephalopathy | Axcella Health, Inc | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AXA1665 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04816916 ↗ |
| Modality | Other / unclassified | “AXA1665, an orally active mixture of amino acids” NCT04816916 ↗ |